Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content. Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

Genmab Shares Drop On Legal Battle With J&J Over Cancer Drug

(Reuters) Sept 23, 2020 - Shares in Danish biotech firm Genmab fell as much as 14% on Wednesday after it said it was locked in a legal battle with its partner Johnson & Johnson over royalty payments for its key cancer drug. Genmab, which specialises in the development of antibody therapeutics for cancer treatment, currently receives royalties from Janssen, a Johnson & Johnson company, for sales of its blockbuster Darzalex drug for treatment of multiple myeloma.

Promega Developing OncoMate™ MSI Assay as Companion Diagnostic for Endometrial Cancer Drug Candidate from Incyte

(Promega) Sept 22, 2020 - Promega Corporation announced today its intent to develop the Promega OncoMate™ microsatellite instability (MSI) Assay as a companion diagnostic test for retifanlimab, Incyte’s anti-PD-1 drug candidate, in endometrial cancer.

No Survival Advantage From Radical Hysterectomy In Patients With Cervical Cancer And Intraoperative Detection Of Positive Lymph Node Involvement

(ESMO 2020) Sept 22, 2020 - No significant difference was observed in the risk of recurrence, local recurrence, or death between patients with cervical cancer in whom radical uterine procedure (mostly radical hysterectomy) was completed or abandoned upon intraoperative detection of a positive pelvic lymph node (LN).

Cancer Centers Nationwide Join To Address The Impact Of Covid-19 Pandemic On Cancer Prevention And Treatment

(UAB) Sept 22, 2020 - A consortium of 17 cancer centers in the United States, including the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham have come together to better understand the consequences of the COVID-19 pandemic in delaying cancer detection, care and prevention.

Novel IAP Drug Shows Promise in Head and Neck Cancer

(MedPage Today) Sept 21, 2020 - An investigational inhibitor of apoptosis proteins (IAPs) extended survival in locally advanced head and neck squamous cell carcinoma (SCC) when added to standard chemoradiotherapy, according to an updated analysis of a phase II study.

New NCCN Resource for Understanding Childhood Leukemia

(NCCN) Sept 23, 2020 - New NCCN Guidelines for Patients: Pediatric Acute Lymphoblastic Leukemia offers a comprehensive look at the latest expert recommendations for treating a common, highly-curable childhood and adolescent cancer; marking the first patient resource from the National Comprehensive Cancer Network focused primarily on children.

Certain Cancer Treatments May Heighten Danger From COVID-19

(U.S. News & World Report/HealthDay News) Sept, 22, 2020 - People with cancer are at increased risk for severe COVID-19. Now, a preliminary study suggests that certain cancer therapies may heighten those odds even further.

Behind the Curtain: 2020 Innovator Award Winners and Their Champions Share the Secrets to their Success

(ACCCBuzz Blog) Sept 22, 2020 - Day 4 of the ACCC 37th [Virtual] National Oncology Conference gave participants the opportunity to connect directly with this year’s ACCC Innovator Award winners and their physician and/or administrative champions.

Study Identifies Genomic Predictors Of Outcomes In High-risk Bladder Cancer

(BIDMC) Sept 22, 2020 - Primarily diagnosed in older adults, bladder cancer disproportionately affects men, striking them about three times as often as women.

FDA Poised To Announce Tougher Standards For A Covid-19 Vaccine That Make It Unlikely One Will Be Cleared By Election Day

(Washington Post) Sept 23, 2020 - The guidance is part of an effort to boost transparency and public trust as polls show many are skeptical a vaccine will be safe and effective.